María Vidal
Hospital Clínic de Barcelona · 343 works · 11,374 citations · h-index 43
Top works
- A variant associated with nicotine dependence, lung cancer and peripheral arterial disease
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- Frequency and spectrum of PIK3CA somatic mutations in breast cancer
- Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
- Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
- HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
- Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
- Predicting response and survival in chemotherapy-treated triple-negative breast cancer
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
- A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
- Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
- Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
- A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade